Patents by Inventor Stacey R. Dillon
Stacey R. Dillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8383775Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: December 29, 2011Date of Patent: February 26, 2013Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8361470Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.Type: GrantFiled: May 17, 2012Date of Patent: January 29, 2013Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120264168Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: February 27, 2012Publication date: October 18, 2012Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Publication number: 20120225065Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: May 17, 2012Publication date: September 6, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Publication number: 20120207761Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: March 22, 2012Publication date: August 16, 2012Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
-
Publication number: 20120208772Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: December 29, 2011Publication date: August 16, 2012Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8241629Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: December 17, 2010Date of Patent: August 14, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 8227575Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: November 25, 2009Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8226948Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: January 11, 2012Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120177655Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Publication number: 20120156210Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: January 12, 2012Publication date: June 21, 2012Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Yasmin A. CHANDRASEKHER, Stacey R. DILLON, Joyce M. LEHNER, Anthony W. SIADAK, Pallavur V. SIVAKUMAR, Margaret Dow MOORE
-
Patent number: 8163286Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: October 16, 2009Date of Patent: April 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Patent number: 8124088Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: GrantFiled: April 14, 2009Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
-
Patent number: 8124089Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: June 11, 2009Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 8110180Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: October 20, 2006Date of Patent: February 7, 2012Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Publication number: 20110318354Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: April 13, 2011Publication date: December 29, 2011Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Patent number: 8017343Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: October 19, 2006Date of Patent: September 13, 2011Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 7998468Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: May 20, 2009Date of Patent: August 16, 2011Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Publication number: 20110130548Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: December 17, 2010Publication date: June 2, 2011Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 7883700Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: December 8, 2008Date of Patent: February 8, 2011Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi